John Wiley & Sons acquires SimBioSys, terms not disclosed John Wiley & Sons announced that it has acquired SimBioSys, a provider of scientific software tools that facilitate the drug discovery process. Terms were not disclosed.
John Wiley & Sons sees Q3 restructuring charge of about $18M The company expects to record a restructuring charge of approximately $18M in the third quarter. Roughly half of the expected charge is related to the completion of facility consolidations and dispositions in connection with prior restructuring actions. The restructuring charge will also include severance costs for reorganization and consolidation plans, primarily in Research and books, consistent with the November reorganization announcement.